Form 4: Revolution Medicines' General Counsel, Jeff Cislini, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Jeff Cislini, General Counsel of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On October 11, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, exercised stock options to acquire 6,000 shares of common stock at a price of $36.57 per share.
• Simultaneously, Cislini sold 6,000 shares of common stock at a weighted average price of $50.1711 per share, with individual sales prices ranging from $50.00 to $50.45.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 20, 2024.
• Following these transactions, Cislini beneficially owns 45,634 shares of Revolution Medicines common stock, which includes 40,209 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no inherent positive or negative implication.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the General Counsel, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Insider trading activity is common across publicly traded companies, and the use of 10b5-1 trading plans is a standard practice to avoid accusations of trading on non-public information.
• Comparing Cislini's transactions to those of other General Counsels in similarly sized biotech companies would provide a better benchmark, but that data is not available in this document.
• Companies like Amgen, Gilead, and Regeneron also have executives who regularly file Form 4s, reflecting their ongoing stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by increasing the float of available shares.
• The filing provides transparency to stakeholders regarding insider trading activity.

Key Dates